Phip.hcl: Carcinogenic Potency Database

PhIP.HCl
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
hmo lgi pro smi	lgi mgl	hmo	hmo	1.78^m	33.2^m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: hmo = hematopoietic system. lgi = large intestine. mgl = mammary gland. pro = prostate. smi = small intestine. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

PhIP.HCl: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



PhIP.HCl  (2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine.HCl) ---
5085 M f cdf eat 82w82 1872                          0    52.0mg                             Esumi;gann,80,1176-1178;1989/pers.comm.
 --- lym e      22.4mg   P<.0005 +  12.6mg 50.4mg   6/40   26/38
5086 M m cdf eat 82w82 1872                          0    48.0mg
 --- lym e      63.9mg   P<.004  +  28.9mg 513.mg   2/36   11/35
5087 R m f34 eat 52w52 2300                          0    6.38mg                               Rao;canr,56,3395-3398;1996/pers.comm.
 --- lym ersv   .789mg   P<.0005 +  .475mg 1.41mg   0/12   27/36
 thm lym ersv   1.07mg   P<.0005 +  .637mg 2.06mg   0/12   23/36
 itn mix ersv   3.36mg   P<.02   +  1.63mg n.s.s.   0/12   10/36
 smi tum ersv   5.06mg   P<.04      2.18mg n.s.s.   0/12    7/36
 col tum ersv   12.6mg   P<.2       3.80mg n.s.s.   0/12    3/36
5088 R f f3d eat 52w52 1922m                         0    20.0mg                   Ito;carc,12,1503-1506;1991/Shirai 1997/pers.comm.
 mgl adc ej     5.45mg   P<.0005 +  2.90mg 12.0mg   0/40   14/30
 col adc ej     49.7mg   P<.07      12.2mg n.s.s.   0/40    2/30
 liv tum ej     no dre   P=1.       30.9mg n.s.s.   0/40    0/30
5089 R f f3d eat 24m24 2062m                         0    1.25mg  5.00mg      Hasegawa;carc,14,2553-2557;1993/Shirai 1999/pers.comm.
 mgl adc ej     6.34mg * P<.0005 +  3.51mg 13.1mg   0/30    2/30   14/30
 col adc ej     30.4mg * P<.008     10.5mg 584.mg   0/30    0/30    4/30
 liv nnd ej     no dre   P=1.       28.8mg n.s.s.   2/30    2/30    0/30
 mgl ade ej     no dre   P=1.       20.3mg n.s.s.   3/30    4/30    1/30
 mgl fba ej     no dre   P=1.       3.19mg n.s.s.   8/30    5/30   (1/30)
5090 R f f3d eat 54w54 2195                          0    10.0mg                          Hasegawa;carc,16,2243-2246;1995/pers.comm.
 mgl adc er     3.62mg   P<.0005 +  1.62mg 11.4mg   0/20    8/20
 col ade er     17.5mg   P<.1       4.31mg n.s.s.   0/20    2/20
 mgl fba er     17.5mg   P<.1       4.31mg n.s.s.   0/20    2/20
5091 R f f3d eat 52w52 2249                          0    10.0mg                              Hirose;carc,16,217-221;1995/pers.comm.
 mgl mix e      2.87mg   P<.004  +  1.33mg 13.8mg   0/10    9/20
 mgl adc e      3.35mg   P<.006  +  1.50mg 28.0mg   0/10    8/20
 lgi mix e      16.3mg   P<.2       3.99mg n.s.s.   0/10    2/20
 mgl fba e      16.3mg   P<.2       3.99mg n.s.s.   0/10    2/20
 lgi car e      30.0mg   P<.4       4.88mg n.s.s.   0/10    1/18
 lgi ade e      30.0mg   P<.4       4.88mg n.s.s.   0/10    1/18
 liv tum e      no dre   P=1.       10.3mg n.s.s.   0/10    0/20
5092 R f f3d eat 54w54 2612                          0    10.0mg                                       Hagiwara;gann,90,399-405;1999
 mgl adc e      3.62mg   P<.006  +  1.62mg 30.2mg   0/10    8/20
 mgl mix e      3.62mg   P<.006  +  1.62mg 30.2mg   0/10    8/20
 col mix e      11.4mg   P<.2    +  3.43mg n.s.s.   0/10    3/20
 col adc e      17.5mg   P<.2    +  4.31mg n.s.s.   0/10    2/20
5093 R m f3d eat 52w52 1922m                         0    16.0mg                   Ito;carc,12,1503-1506;1991/Shirai 1997/pers.comm.
 pro car Cej    2.49mg   P<.0005 +  1.38mg 5.03mg   0/37   18/27
 col adc ej     3.42mg   P<.0005 +  1.87mg 7.13mg   0/40   16/29
 liv tum ej     no dre   P=1.       23.9mg n.s.s.   0/40    0/29
5094 R m f3d eat 24m24 2062m                         0    1.00mg  4.00mg      Hasegawa;carc,14,2553-2557;1993/Shirai 1999/pers.comm.
 --- lle ej     5.92mg * P<.003  +  2.85mg 38.2mg   3/30    6/30   13/30
 col adc ej     6.44mg * P<.0005 +  3.37mg 14.6mg   0/30    0/30   13/30
 liv nnd ej     4.62mg \ P<.08      1.51mg n.s.s.   1/30    5/30   (1/30)
 pro car ej     18.5mg * P<.6       2.75mg n.s.s.  10/25   13/25   11/22
 mgl fba ej     no dre   P=1.       12.2mg n.s.s.   2/30    2/30    2/30
5095 R f sdf eat 52w52 2525                          0    5.53mg                                     Weisburger;jepo,16,329-334;1997
 mgl mix v      .826mg   P<.0005 +  .462mg 1.80mg   1/18   21/30
 col adc v      13.7mg   P<.2       3.38mg n.s.s.   0/18    2/30
5096 R f sdj eat 48w48 2233m ()                      0    1.25mg  5.00mg  10.0mg            Imaida;gann,87,1116-1120;1996/pers.comm.
 mgl mix Cer    1.54mg * P<.0005 +  .882mg 3.26mg   1/20    1/21    7/20   13/18
 mgl adc Cer    1.67mg * P<.0005 +  .960mg 3.26mg   0/20    1/21    5/20   13/18
 mgl dpp Cer    44.3mg * P<.5       7.22mg n.s.s.   0/20    0/21    1/20    0/18
 mgl fba Cer    no dre   P=1.       8.97mg n.s.s.   1/20    0/21    1/20    0/18
5097 R f sdj eat 48w48 2233n ()                      0    .625mg  2.50mg
 mgl mix Cer    .797mg * P<.005  +  .356mg 8.02mg   1/20    3/20    8/20
 mgl adc Cer    .851mg * P<.002  +  .399mg 3.21mg   0/20    2/20    7/20
 mgl fba Cer    4.86mg * P<.4       1.09mg n.s.s.   0/20    1/20    1/20
 mgl dpp Cer    no dre   P=1.       .439mg n.s.s.   1/20    0/20    0/20

Mutagenicity in Salmonella: positive
SMILES Code for PhIP.HCl: N1(=C2C(=CC(=C1)C3=CC=CC=C3)N(C(=N2)N)C).[H]Cl
InChI Code for PhIP.HCl: InChI=1/C13H12N4.ClH/c1-17-11-7-10(9-5-3-2-4-6-9)8-15-12(11)16-13(17)14;/h2-8H,1H3,(H2,14,15,16);1H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007